AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00473889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: carboplatin
Description: intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
Study NCT00473889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: carboplatin
Description: intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
Study NCT03941119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-therapy
Description: Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
Study NCT04192916 — intervention group
Intervention type: DRUG
Intervention: DOACs
Description: Direct Oral Anticoagulants
Study NCT03655262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconscious Neuro-reinforcement
Description: Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
Study NCT00473889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
Study NCT00811954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
Study NCT00811954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg taken orally twice daily. An integrase inhibitor (INI).
Study NCT00811954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800 mg taken orally once daily. A protease inhibitor (PI).
Study NCT00811954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).
Study NCT03208712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV once every 3 weeks
Study NCT03208712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
Study NCT04622722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutren Diabetes
Description: Nutren Diabetes provides energy at 360 kcal per 360 ml
Study NCT04622722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutren Diabetes
Description: Nutren Diabetes provides energy at 360 kcal per 360 ml
Study NCT04622722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric
Description: Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
Study NCT04622722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric
Description: Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
Study NCT00632203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
Study NCT01579968 — intervention group
Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
Study NCT03292120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measure of the SOFA score
Description: The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
Study NCT01622400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education HTA Vasc
Description: The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
Study NCT03989024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin
Description: Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
Study NCT03989024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
Study NCT03928522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hand mixed vancomycin
Description: hand mixed vancomycin powder into cement
Study NCT03928522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hand mixed vancomycin
Description: hand mixed vancomycin powder into cement
Study NCT03928522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hand mixed tobramycin
Description: hand mixed tobramycin into cement
Study NCT03928522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hand mixed tobramycin
Description: hand mixed tobramycin into cement
Study NCT00811954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg taken orally once daily. A protease inhibitor (PI).
Study NCT03928522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pre-mixed tobramycin
Description: this cement is already pre-mixed with tobramycin
Study NCT00780351 — intervention group
Intervention type: DEVICE
Intervention: sustained low efficiency daily hemodiafiltration (SLEDD-f)
Description: vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
Study NCT04526067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAT
Description: An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.
Study NCT04526067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R-CAT
Description: An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
Study NCT00765713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure
Description: Nocturnal
Study NCT00003203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00003203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00003203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00003203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00003203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00003203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00003203 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy/fx x 20fx=36Gy Craniospinal XRT\*
Study NCT00927264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Intervention for ETS Reduction
Description: The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits \& 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
Study NCT00927264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program for ETS Reduction
Description: An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
Study NCT02641314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronomic therapy
Description: * Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose
Study NCT02472795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Study NCT02472795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Study NCT04134741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic Control
Description: The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes.
Study NCT03726333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorlatinib
Description: continued daily administration of 100 mg lorlatinib
Study NCT03726333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorlatinib
Description: continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
Study NCT03726333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: continued daily administration of 100 mg QD lorlatinib
Study NCT03726333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
Study NCT03726333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorlatinib
Description: continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
Study NCT01081717 — intervention group
Intervention type: DRUG
Intervention: systemic non-biological treatments
Description: as prescribed
Study NCT01081717 — intervention group
Intervention type: BIOLOGICAL
Intervention: anti-TNF biologics
Description: as prescribed
Study NCT01081717 — intervention group
Intervention type: BIOLOGICAL
Intervention: golimumab
Description: as prescribed
Study NCT01081717 — intervention group
Intervention type: BIOLOGICAL
Intervention: non-anti-TNF biologics
Description: as prescribed
Study NCT01081717 — intervention group
Intervention type: OTHER
Intervention: general population
Description: non-treated cohort
Study NCT00373490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
Study NCT00373490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
Study NCT03710265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study NCT03194399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized health care service
Description: Physical activity coaching, other functional outcome observation
Study NCT02921295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sidekick Stubbies
Study NCT04456959 — intervention group
Intervention type: DRUG
Intervention: Inotuzumab Ozogamicin
Description: Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
Study NCT02625987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous intradermic stitch
Description: Appendectomy wound closure with an intradermic Polyglactina 910 stitch
Study NCT02625987 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Separated stitches
Description: Appendectomy wound closure with a separated stitches.
Study NCT03811522 — intervention group
Intervention type: OTHER
Intervention: carbon dioxide insufflation
Description: Receives CO2 insufflation
Study NCT03811522 — intervention group
Intervention type: OTHER
Intervention: Air insufflation
Description: Receives air insufflation
Study NCT01575587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment A
Description: 1000 mg abiraterone acetate administered in the fasting state
Study NCT01575587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment B
Description: Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
Study NCT01575587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment C
Description: Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
Study NCT01575587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone: Treatment D
Description: Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
Study NCT03247751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraocular lens
Description: Implant NIDEK intraocular lens after cataract surgery
Study NCT02231008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Study NCT02231008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02285842 — intervention group
Intervention type: DEVICE
Intervention: Primary hip resurfacing device
Description: CONSERVE® Press-Fit Femoral Components
Study NCT00159120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maintained antipsychotic treatment vs. stepwise drug discontinuation
Description: maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
Study NCT00159120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maintained antipsychotic treatment vs. stepwise drug discontinuation
Description: maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
Study NCT00687960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch type 4 - raw
Description: Dose: 80g bar containing Resistant Starch Type 4 - raw
Study NCT00687960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4 - Cooked
Description: Dose: 80g bar containing Resistant Starch Type 4 - cooked
Study NCT00687960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: Dose: 7 oz of oral glucose tolerance beverage
Study NCT00687960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Puffed Wheat
Description: Dose: 80g bar containing puffed wheat cereal
Study NCT00358371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucloxacillin 250 mg
Description: Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
Study NCT00358371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucloxacillin 500 mg
Description: Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
Study NCT02416921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-gain Prevention
Description: A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
Study NCT02416921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Women's Health
Description: A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
Study NCT04190680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kokkerelli Learning Street
Description: The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher.
Study NCT03071861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
Study NCT03071861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single dose of normal saline, IV, given at less than 24 hours of age
Study NCT04527055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Subcitrate 120 MG Oral Tablet
Description: Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study NCT04209530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Collagenase Clostridium Histolyticum (CCH)
Study NCT00556335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual aspiration
Description: air aspiration
Study NCT00556335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional drainage
Description: drainage, pneumocath
Study NCT04712266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: calculated IV insulin:Glucagon molar ratio
Study NCT04712266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: calculated IV Insulin dose infused at a constant rate
Study NCT04712266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: calculated IV Insulin dose infused at a constant rate